- Home
- PMVP vs WHWK Comparison
PMVP vs WHWK Comparison
Compare PMVP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- WHWK
- Stock Information
- Founded
- PMVP 2013
- WHWK 2007
- Country
- PMVP United States
- WHWK United States
- Employees
- PMVP 47
- WHWK N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- WHWK Health Care
- Exchange
- PMVP Nasdaq
- WHWK Nasdaq
- Market Cap
- PMVP 82.1M
- WHWK 82.4M
- IPO Year
- PMVP 2020
- WHWK N/A
- Fundamental
- Price
- PMVP $1.48
- WHWK $1.82
- Analyst Decision
- PMVP Strong Buy
- WHWK
- Analyst Count
- PMVP 1
- WHWK 0
- Target Price
- PMVP $5.00
- WHWK N/A
- AVG Volume (30 Days)
- PMVP 364.5K
- WHWK 112.4K
- Earning Date
- PMVP 08-07-2025
- WHWK 08-07-2025
- Dividend Yield
- PMVP N/A
- WHWK N/A
- EPS Growth
- PMVP N/A
- WHWK N/A
- EPS
- PMVP N/A
- WHWK N/A
- Revenue
- PMVP N/A
- WHWK $21,596,000.00
- Revenue This Year
- PMVP N/A
- WHWK N/A
- Revenue Next Year
- PMVP N/A
- WHWK N/A
- P/E Ratio
- PMVP N/A
- WHWK N/A
- Revenue Growth
- PMVP N/A
- WHWK N/A
- 52 Week Low
- PMVP $0.81
- WHWK $1.39
- 52 Week High
- PMVP $1.82
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- PMVP 56.79
- WHWK 56.72
- Support Level
- PMVP $1.38
- WHWK $1.76
- Resistance Level
- PMVP $1.59
- WHWK $1.87
- Average True Range (ATR)
- PMVP 0.10
- WHWK 0.07
- MACD
- PMVP -0.00
- WHWK 0.02
- Stochastic Oscillator
- PMVP 65.52
- WHWK 87.73
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.